Research Alliance CORP Iii

Research Alliance Corporation III (RACC) announced a business combination agreement with Oak Hill Bio, a rare disease therapeutics company, to form Oak Hill Bio, Inc., expected to trade on Nasdaq under OAKH.

Research Alliance Corporation III (RACC) reports on its Q2 2026 financial status, highlighting progress towards its business combination with OHB Pediatrics Ltd. and maintaining a strong cash position.

Research Alliance Corporation III, a blank check company, filed its quarterly report for the period ended March 31, 2026, detailing its formation activities and upcoming initial public offering.

Oak Hill Bio merges with Research Alliance Corporation III (SPAC) to fund its Angelman syndrome drug development, aiming for Nasdaq listing.

Research Alliance Corporation III (RACC) has entered into a definitive business combination agreement with OHB Pediatrics Ltd. (Oak Hill Bio) to form a new publicly traded rare disease biotechnology company.

Research Alliance Corporation III has entered into a Business Combination Agreement to acquire OHB Pediatrics Ltd., with an expected closing in the second half of 2026.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.4% of Research Alliance Corporation III's Class A Ordinary Shares.

TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC, and Chen Yu have jointly reported beneficial ownership of 500,000 Class A Ordinary Shares, representing 6.4% of the outstanding shares in Research Alliance Corporation III.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 500,000 shares, representing 6.43% of Research Alliance Corporation III's Class A Common Stock.

Spruce Street Capital LP, along with its managing members Alex R. Rosen and Simon Basseyn, has reported beneficial ownership of 6.4% of Research Alliance Corp III's Class A Ordinary Shares.

Bank of America Corporation has reported beneficial ownership of 503,914 Class A Ordinary Shares, representing 6.5% of the outstanding shares, in Research Alliance Corp III.